“While orphan drugs’ share of the $880-billion global pharmaceuticals market remains small—at $50 billion as of the end of 2011, or just 6% of the total—their growth curve has been steep. Thomson Reuters reports that between 2001 and 2010, orphan drugs posted a compound annual growth rate of 25.8%, outstripping the 20.1% CAGR returned by a matched non-orphan control group. With these kinds of eye-popping profits being raked in by orphan drug makers, the investment world has taken notice.”
http://www.caseyresearch.com/cdd/orphans-adding-company-value-in-the-biotech-space
Related posts:
The More Attention on The Next Fed Chair, The Better!
Premeditation of Currency Wars
How to Keep the NSA From Spying Through Your Webcam
Doug Casey in Cyprus: Crisis Investing in Action
Illinois Legislative Leaders Sue Governor Over Vetoing Lawmakers' Pay Raise
Why Bitcoins Are Just Like Gold
Boulder DA Stops Marijuana Possession Prosecutions
A Government Database about our Sex Lives: Gee, What Could Go Wrong?
Man angry over Boston bombings breaks jaw of ‘f*cking Muslim’ Iraq war veteran
At Davos the Elite Ponder Stale Cybersecurity Issues—and Charlize Theron
State Dept. Wants All Visa Applicants To Provide Their Social Media Information
Baidu-owned Hao123 Launches Dedicated Bitcoin News Portal
Iowa Judge Rescues Sioux City Speed Camera Program
Man With Down Syndrome Killed By Police Over $11 Movie Ticket
Should You Renounce Your U.S. Citizenship?